CytomX Therapeutics (CTMX)
(Real Time Quote from BATS)
$2.19 USD
-0.18 (-7.60%)
Updated Aug 6, 2025 03:22 PM ET
3-Hold of 5 3
B Value C Growth F Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CTMX 2.19 -0.18(-7.60%)
Will CTMX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CTMX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CTMX
CytomX Therapeutics (CTMX) Beats Q1 Earnings and Revenue Estimates
SpringWorks Therapeutics (SWTX) Reports Q1 Loss, Misses Revenue Estimates
CTMX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue Estimates
ANI Pharmaceuticals to Report Q1 Earnings: Is a Beat in the Cards?
Perrigo to Report Q1 Earnings: Is a Beat in Store for the Stock?
Other News for CTMX
This Lexeo Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday
Franklin Biotechnology Discovery Fund Q2 2025 Commentary
Deep Dive Into CytomX Therapeutics Stock: Analyst Perspectives (4 Ratings)
CytomX Therapeutics (CTMX) Receives 'Outperform' Rating from Oppenheimer | CTMX Stock News
CytomX Therapeutics to Report Second Quarter 2025 Financial Results on August 7, 2025 | CTMX ...